Effective contraception for HIV-infected women is vital to prevent unplanned pregnancies that could lead to perinatal acquisition of HIV infection and exposure to potentially teratogenic medications used as part of an antiretroviral (ARV) regimen [1, 2] .
Efavirenz is a non-nucleoside reverse transcriptase inhibitor recommended for the treatment of HIV type-1 infection in adults and adolescents [3, 4] . Animal data suggest that fetal exposure to efavirenz might have the potential to cause harm when administered to a pregnant woman during the first trimester [5, 6] . Efavirenz is a US pregnancy category D medication; therefore, pregnancy prevention is essential in women receiving efavirenz as part of their antiretroviral therapy (ART).
Oral contraceptives (OCs) containing a combination of ethinyl estradiol (EE) and a progestin are among the most effective and frequently used methods of birth control, with preparation components carefully selected to achieve the required balance of a regulated menstrual cycle and the prevention of pregnancy [7, 8] . However, the coadministration of OCs with ARV regimens containing efavirenz in HIV-infected women might be complicated by drug interactions [9] . For example, it is known that efavirenz is an inducer of hepatic cytochrome P450 (CYP)3A4 and uridine-diphosphate glucuronosyl transferases (UGTs) in vivo [5, 10] , both of which are involved in the metabolic pathways of EE [11] . Although the specific enzymes involved in progestin metabolism have not been well-defined, CYP3A4 and UGTs might play a role [12] . Therefore, as a result of drug interactions, exposure to OC components could be adversely affected when coadministered with
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The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women A previous study investigating the effect of efavirenz on the single-dose pharmacokinetics (PK) of EE showed that administration of efavirenz at a daily dose of 400 mg for 7 days increased the peak plasma concentration (C max ) and area under the concentration-time curve (AUC) of EE by 5% and 37%, respectively [5] . Only a single dose of an OC was administered, the dose of efavirenz used in that study was below the clinically recommended 600 mg per day and treatment was given for a period of time too short for the full induction potential of efavirenz to be realized. Thus, the effect of efavirenz on EE has not been completely characterized. Additionally, the PK of the progestin components of an OC were not measured. Therefore, the effect of efavirenz on the PK of progestins, adequate levels of which are especially vital to contraceptive efficacy, has not been characterized.
Efavirenz is primarily metabolized by CYP2B6 and CYP3A4 [5, 6] . Data regarding the effect of OCs on these two enzymes are very limited, although a combined OC containing EE and desogestrel has been shown to inhibit the hydroxylation of a CYP2B6 substrate, bupropion, by 31% [13] . Data are inconsistent regarding the effects of OC components on CYP3A4 metabolism [14] [15] [16] ; therefore it is possible that coadministration with a combined OC could result in altered efavirenz exposure.
The present study was designed to examine the effect of the clinical dose of efavirenz (600 mg once daily) on the PK of EE and the active metabolite of the progestin norgestimate (NGM), 17-deacetyl NGM (also known as norelgestromin [NGMN] ), in healthy HIV-negative women. A post hoc exploratory analysis of the effect of efavirenz on the PK of levonorgestrel (LNG), another active metabolite of NGM, was conducted in a subset of patients after the results of the effect of efavirenz on NGMN were available. Although LNG is normally present in low concentrations relative to NGMN, it might also play an important role in contraceptive efficacy [17] . The OC preparation Ortho Cyclen ® (given initially as Ortho Tri-Cyclen ® LO to ensure synchronization of the menstrual cycles of all participants, then as Ortho Cyclen; Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, NJ, USA), was selected for this study because it is one of the most commonly prescribed OC formulations and it allows a comparison to be made of the effects of efavirenz on exposures of higher-dose contraceptive preparations with exposures of effective preparations with lower contraceptive doses.
Methods

Study design and population
The study was an open-label three-period fourtreatment single-sequence one-way drug interaction study in healthy HIV-negative female participants. The study was conducted at two clinical sites in the US from December 2006 through September 2007. An institutional review board or ethics committee at the study sites approved the study protocol and the informed consent form. Written informed consent was obtained from all women prior to participation in the study.
The [19] , and those with satisfactory safety results began a second cycle of Ortho Cyclen (days 57-77; period 3) coadministered with efavirenz 600 mg once daily for 14 days (days 57-70; treatment C). On days 71-77 of period 3, participants continued with Ortho Cyclen alone (treatment D).
During periods 1 and 2, Ortho Tri-Cyclen LO and Ortho Cyclen were taken by participants at home, except on days 13-15, 41-43 and 56, when participants were required to return to the study centre for safety evaluations and PK sample collections. During period 3, Ortho-Cyclen was taken in the clinic as participants were required to be admitted to the study centre for the entire treatment period (days 57-77). All treatments were dosed in the evening before bedtime.
Participant eligibility and restrictions
Healthy HIV-negative female participants, as determined by medical history, physical examination, 12-lead electrocardiogram (ECG) and clinical laboratory evaluations, aged 18-45 years and with a body mass index (BMI) of 16-32 kg/m 2 , were eligible to participate in the study. Participants were required to be on a stable regimen of OCs for ≥2 months prior to study dosing and to have negative pregnancy tests.
Study assessments and data collection
Participants were required to complete a diary card with dosing times of OCs and any AEs, including breakthrough bleeding/spotting, that they experienced while furloughed from the clinical facility. Follow-up visits were conducted on day 85 ±2 and on day 108 ±2 for pregnancy testing and AEs.
Pharmacokinetic and pharmacodynamic sample collection and analyses
Blood samples were collected up to 24 h post-dose on days 14, 42 and 70 for EE analysis, on days 42 and 70 for NGMN analysis, on day 70 for efavirenz analysis and in a subset of six participants for LNG analysis, performed post hoc on days 42 and 70.
Samples were assayed using liquid chromatography-tandem mass spectrometry with standard curves (QC deviations from nominal concentration) ranging from 10-500 pg/ml (±6.06%) for EE, 101-5,050 pg/ ml (±6.69%) for NGMN, 10-10,000 ng/ml (±1.00%) for efavirenz and 50.4-10,080 pg/ml (±6.20%) for LNG. Intraday variability for EE, NGMN, efavirenz and LNG were 15.8%, 4.98%, 5.25% and 4.42%, respectively, whereas interday variability values for each analyte were 3.29%, 3.34%, 8.05% and 0.00%, respectively.
PK parameters were estimated using non-compartmental methods (Kinetica™ version 4.4.1, Thermo Electron Corporation, Philadelphia, PA, USA). The C max , time of peak plasma concentration (T max ), AUC for a dosing interval (AUC [t] ), and lowest plasma concentration (C min ) were derived from the plasma concentration-time profiles on days 14, 42 and 70 for EE, days 42 and 70 for NGMN and LNG, and on day 70 for efavirenz.
Blood samples for endogenous progesterone measurements were collected on day 2 and once during each treatment period on days 18, 46 and 74 as a biomarker for possible ovulation.
Safety analyses
Analysis of safety was based on medical review of AE reports, vital signs, 12-lead ECGs, physical examination findings and laboratory results.
Statistical analyses
The effect of efavirenz on the PK of EE, NGMN and LNG was estimated by comparing C max , AUC (t) and C min for EE, NGMN and LNG in the presence of efavirenz with the same parameters in the absence of efavirenz (treatment C versus treatment B). The results were presented as ratios of adjusted geometric means and 90% confidence intervals (CIs) derived by fitting general linear models to log transformed data with treatment as a fixed effect and measurements within each participant as repeated measurements. Point estimates and 90% CIs for differences on the log scale were exponentiated to obtain estimates for ratios of geometric means on the original scale. The treatment period when participants were not receiving efavirenz (treatment B) was the reference for all comparisons. No adjustments were made for multiplicity.
PK parameters for efavirenz when coadministered with Ortho Cyclen were summarized using geometric means and assessed relative to historical data using scatter plots. The historical data included steady-state PK parameters (C max , AUC [t] and C min ) for efavirenz 600 mg (alone) administered once daily for 14 days in all female participants (n=18) from three studies in healthy volunteers.
Differences in endogenous progesterone levels between treatments and their corresponding 95% CIs were estimated using general linear models with treatment as a fixed effect and measurements within each participant as repeated measurements.
All available data from participants who received study drug and had valid concentration data were included in the PK data set. All PK parameters from adequate PK profiles were included in the statistical analysis. All participants who received study medication were included in the safety data set. Statistical analyses were carried out using SAS/STAT ® version 8.2 (SAS Institute, Inc., Cary, NC, USA).
Results
A total of 28 participants were enrolled and dosed and 19 participants completed the study. Of the nine participants who discontinued, five withdrew consent, two were discontinued because of poor adherence and two because of a positive drug screen.
The median age of participants was 26 years (range 18-42). The group comprised 68% of participants who were White, 21% Black, 4% Hawaiian/Pacific Islander and 7% other ethnicity. The median BMI of the study group was 25.1 kg/m 2 (range 19.7-32.0).
PK of EE
PK results for EE are shown in Table 1 . The mean plasma concentration-time profiles for EE in the 24 h after dosing, in the presence or absence of efavirenz, are shown in Figure 1A . Exposures to EE following coadministration of efavirenz and Ortho Cyclen (treatment C) were similar to those after administration of Ortho Cyclen alone (treatment B); the 90% CIs for the ratio of geometric means for C max and AUC (t) fell within the equivalence ratio of 0.80-1.25 as defined in the FDA Drug Interaction Guidance [20] . Figure 2A shows the comparison of EE AUC (t) for each individual patient.
PK of progestins: NGMN and LNG
Results for NGMN PK parameters are shown in Table 2 . The mean plasma concentration-time profiles for NGMN in the 24 h after dosing, in the presence or absence of efavirenz, are shown in Figure 1B . Exposures to NGMN were substantially decreased following coadministration of efavirenz and Ortho Cyclen (treatment C) relative to administration of Ortho Cyclen alone (treatment B). The adjusted geometric means for NGMN C max , AUC (t) and C min were decreased by 46% (90% CI 39-52), 64% (90% CI 62-67) and 82% (90% CI 79-85), respectively. , pg•h/ml 27,000 Figure 2B shows the comparison of NGMN AUC (t) for each individual patient.
Results from a post hoc exploratory analysis of the effect of efavirenz on LNG PK parameters, conducted in six participants after the results of NGMN were available, are shown in Table 2 . The mean plasma concentration-time profiles for LNG in the 24 h after dosing, in the presence or absence of efavirenz, are shown in Figure 1C . LNG exposures showed a similar to greater decrease as noted for NGMN following coadministration of efavirenz and Ortho Cyclen (treatment C) relative to administration of Ortho Cyclen alone (treatment B). The adjusted geometric means for LNG C max , AUC (t) and C min were decreased by 80-86%. Figure 2C shows the comparison of LNG AUC (t) for each individual patient.
PK of efavirenz
Efavirenz exposures, presented as geometric means (range), after coadministration of Ortho Cyclen were 6,268 ng/ml (3,260-13,400) for C max , 79,538 ng•h/ ml (41,163-185,506) for AUC (t) and 2,349 ng/ml (1,140-6,300) for C min . These values were comparable to historical data for efavirenz administered alone in healthy females (geometric means of C max 6,680 ng/ml, AUC [t] 84,106 ng•h/ml and C min 2,462 ng/ml; BristolMyers Squibb, unpublished data).
Pharmacodynamics of progesterone
For treatments A, B and C, the adjusted mean endogenous serum progesterone levels were 38.9, 39.9 and 42.9 ng/dl, respectively. The difference in adjusted means point estimates for treatments C and A was 4.0 (90% CI -2.5-10.6) and for treatments C and B was 3.0 (90% CI -5.5-11.5). Thus, single time point endogenous progesterone levels after coadministration of efavirenz and Ortho Cyclen were similar to those observed after administration of Ortho Cyclen alone. All progesterone levels collected at a single time point during coadministration of efavirenz and Ortho Cyclen (treatment C) were <125 ng/dl and thus below the level indicative of ovulation (1,000 ng/dl) [21] .
Safety
There were no deaths or discontinuations because of AEs. Most AEs were mild or moderate in intensity. A total of three severe AEs were reported in three participants, one each because of headache, anhedonia and mental depression. The one serious AE reported during the study -a suicide attempt during the post-treatment follow-up period -occurred in a participant with a prior history of depression requiring medication, which was not disclosed at the time of enrolment.
The most frequently reported treatment-related AEs were metrorrhagia and headache, reported by 5 (23%) and 6 (27%) participants for treatment C (Ortho Cyclen coadministered with efavirenz) and 4 (16%) and 5 (20%) participants for treatment B (Ortho Cyclen alone), respectively. In one participant, there were laboratory abnormalities because of increased aspartate aminotransferase and alanine aminotransferase that were reported as AEs but were not considered related to the study treatments. There were no clinically meaningful changes in vital signs or ECG parameters in participants during the study period.
Discussion
This study represents the first investigation of the effects of efavirenz on the progestin components of OC preparations and on the resulting progestin exposures that are an important determinant of contraceptive efficacy [22] . The results from the study, performed in healthy HIV-negative females, showed that the plasma exposure (AUC [t] ) of the progestin NGMN, an active metabolite of NGM, was decreased by 64% (90% CI 62-67) when the OC Ortho Cyclen was coadministered with the ARV agent efavirenz, administered at the standard daily clinical dose of 600 mg, compared with when Ortho Cyclen was administered alone. Following the observed substantial decrease in NGMN exposure, a post hoc analysis in a small subset of participants found that LNG exposures were also substantially decreased (by 80-86%) when Ortho Cyclen was coadministered with efavirenz compared with when Ortho Cyclen was administered alone.
Although the active metabolites of NGM assessed in this study, namely NGMN, which is primarily responsible for the progestational activity, and LNG, have been defined previously, the specific enzymes responsible for their production and clearance have not been well-characterized [12, 17] . It is thought that NGM and its metabolites, similar to EE, are substrates of both CYP3A4 and UGTs, two enzyme pathways that are known to be induced by efavirenz, resulting in a reduction in progestin exposures during treatment with Ortho Cyclen.
Data from the current study in healthy female participants also demonstrated that coadministration of efavirenz did not significantly affect the PK of EE, despite evidence that efavirenz induces two enzymes involved in the metabolism of EE hepatic CYP3A4 and UGTs [5, 11] . This is in contrast to a previous study that reported a 37% increase in the single dose AUC of EE when coadministered with efavirenz [5] ; however the full induction potential of efavirenz might not have been realized after only 7 days of dosing. The increase in EE exposure observed in that study might be attributed to inhibition of other enzymes or transporters involved in EE disposition.
Indeed, an explanation for a lack of effect of efavirenz on EE exposure observed in the current study might lie with the known actions of efavirenz to simultaneously inhibit and induce a number of the enzymatic pathways (such as cytochromes and the transporter ABCB1) that might be involved in EE metabolism [23, 24] , such that the overall effects of efavirenzrelated enzyme induction and enzyme inhibition are counterbalanced, with no net effect on EE exposures.
Although this was a one-way interaction study the PK parameters for efavirenz when coadministered with Ortho Cyclen were assessed relative to historical data using scatter plots to rule out an unexpected drug interaction with OCs. The efavirenz exposures after coadministration of Ortho Cyclen noted in this study were found to be comparable to historical data for efavirenz when administered alone to healthy female participants, suggesting that the EE and progestin components of Ortho Cyclen do not affect efavirenz PK.
In women taking OCs, exposure to exogenous progestins (and to a lesser extent, to exogenous EE) results in the suppression of ovulation, one manifestation of which is suppressed endogenous progesterone levels. It is known that during treatment with OCs, blood levels of progesterone typically remain below 1.5 ng/ml. In the present study it was shown that all progesterone levels (pretreatment and at a single time point during each treatment period) remained below the concentration indicative of ovulation [21] , and the coadministration of efavirenz with Ortho Cyclen did not change endogenous progesterone levels relative to those seen during Ortho Cyclen administration alone. The observation of unchanged levels of progesterone suggests that ovulation might be successfully suppressed by Ortho Cyclen during efavirenz coadministration despite the demonstrated reductions in exposures to the progestins NGMN and LNG in the presence of efavirenz. However, in this study, progesterone levels were assessed at a single time point within the menstrual and treatment cycle; therefore, the interpretation of progesterone findings requires caution. Indeed, the key finding of clinical relevance from the present study is that efavirenz significantly affects NGMN and LNG levels, supporting the product label recommendation that barrier contraception must be used in addition to hormonal contraception when HIV-infected women take progestin-containing OCs with efavirenz-containing ART.
This study has provided further evidence that efavirenz coadministration with OCs is relatively welltolerated. There were no unexpected AEs reported during coadministration of efavirenz and Ortho Cyclen and all AEs were consistent with those previously reported in clinical experience with each of these therapies. Indeed, there is growing evidence that women receiving ART for the management of HIV infection can use hormonal contraceptives without compromise to the efficacy and safety of their ARV regimen. For example, the safety and efficacy of hormonal contraception among HIV-infected women has been assessed in the Women's Interagency HIV Study, a prospective cohort study, performed in the US in women started on ART since 2001 [25] . In that epidemiological study, the use of hormonal contraception was not associated with changes in circulating HIV RNA levels or CD4 + T-cell count after initiation of ART. Although the current medical literature supports and encourages the use of hormonal contraception in HIV-infected women [1] , there is still a lack of long-term studies of contraception in women living with HIV/AIDS and a lack of specific studies investigating the potential interactions of hormonal contraceptives and ARV medications. This lack of evidence-based research effectively limits the contraceptive options available for recommendation to women with HIV infection.
Two recent studies evaluated the PK of injectable depot medroxyprogesterone acetate (DMPA) in HIVinfected women on therapeutic regimens containing nelfinavir, efavirenz or nevirapine in combination with non-nucleoside reverse transcriptase inhibitors [26, 27] . In both studies, suppression of ovulation was maintained and no significant differences in DMPA PK parameters were found between participants receiving or not receiving ART. The coadministration of DMPA has also been shown not to affect CD4 + T-cell counts or HIV RNA levels in women on stable regimens containing nelfinavir, efavirenz or nevirapine [26, 28] . Taken together, these studies suggest that injectable progestinbased contraception with DMPA might be an option for HIV-infected women receiving selected ART. However, contraceptive failures in HIV-infected women on efavirenz-based ART using implantable devices that release another progestin, etonogestrel, have also been reported in the literature [29] , further reinforcing the growing appreciation that the most reliable method for preventing pregnancy in the HIV-infected female population is to combine hormonal and barrier methods. Further studies are needed to fully explore and investigate the safety and efficacy of hormonal contraception in women on efavirenz-based ART.
Conclusions
Preventing pregnancy is important in HIV-infected women of childbearing age who are receiving efavirenz as part of their ART. Although efavirenz had no significant effect on the PK of EE, it substantially reduced exposures to the progestin components of Ortho Cyclen. Because the contraceptive efficacy of Ortho Cyclen is dependent on adequate progestin levels, the results reinforce the need to use reliable methods of barrier contraception when taking OCs and efavirenz.
